Danaher completes Masimo acquisition
Analysis based on 6 articles · First reported Jun 10, 2026 · Last updated Jun 11, 2026
The completion of the acquisition of Masimo by Danaher Corporation is expected to positively impact Danaher Corporation's stock price due to anticipated earnings accretion and strengthened market position in diagnostics. Masimo's stock has ceased trading on the Nasdaq, indicating a direct impact on its former shareholders who received cash consideration.
Danaher Corporation has completed its acquisition of Masimo_Corporation for $9.5 billion, integrating the specialty diagnostics provider into its Diagnostics segment. Masimo, known for its pulse oximetry and patient monitoring solutions, will now operate as a wholly-owned subsidiary under the Masimo brand, enhancing Danaher Corporation's capabilities in acute care settings. The transaction, which was unanimously approved by both companies' boards and Masimo's shareholders, is expected to be accretive to Danaher Corporation's adjusted diluted net earnings per common share. Following the completion, Masimo common stock ceased trading on the Nasdaq. Danaher Corporation does not anticipate a material contribution from Masimo in the second quarter of 2026 but plans to update its full-year guidance to reflect Masimo's expected contributions.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard